Table 1.

Baseline characteristics of type 2 diabetes patients initiating therapy with exenatide once weekly or liraglutide once daily

Variable	Exenatide once weekly (n=5,449)	Liraglutide once daily (n=24,648)	P-value
Male (%)	51.4	49.7	0.340
Age, years (mean ± SD)	59.7±11.8	59.4±11.4	0.098
Age groups (%)
≤50 years	21.2	21.6	0.632
51–60 years	30.2	31.5	0.167
61–70 years	29.1	29.1	0.965
>70 years	19.6	17.8	0.026
Cotherapy with (%)
Metformin only	35.5	33.2	<0.001
Metformin + sulfonylurea	11.9	10.3	<0.001
Metformin + DPP-4 inhibitors	9.9	6.8	<0.001
Metformin + insulin	11.8	23.1	<0.001
Insulin	3.9	6.4	<0.001
DPP-4 inhibitors	5.4	2.8	<0.001
GLP-1RA monotherapy	13.7	10.9	<0.001
Other combinations	7.9	6.5	0.088

Note: LRx database, January 2011–September 2014, Germany.

Abbreviations: DPP-4, dipeptidyl peptidase 4; GLP-1RA, glucagon-like peptide-1 receptor agonist; LRx, longitudinal prescriptions database.